Evofem Biosciences company information, Employees & Contact Information

Evofem Announces Voting Results from Special Meeting of Stockholders Yahoo Finance

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting Morningstar

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms PR Newswire

Evofem's Q2 Revenue Jumps 16% as TikTok Campaign Goes Viral with 7M Views, Merger Talks Progress Stock Titan

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update PR Newswire

Evofem Reports Fourth Consecutive Year of Net Sales Growth Yahoo Finance

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis PR Newswire

1.7M UAE Women Could Benefit: Evofem's Single-Dose BV Treatment Seeks First International Approval Stock Titan

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates – Company Announcement Financial Times

Evofem Biosciences Honors World Contraception Day PR Newswire

Evofem Biosciences to Present at Emerging Growth Conference PR Newswire

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics PR Newswire

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 PR Newswire

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution PR Newswire

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare PR Newswire

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire

Evofem Acquired by Aditxt for $100M San Diego Business Journal

Evofem Biosciences Announces 1-for-125 Reverse Stock Split PR Newswire

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter PR Newswire

Evofem (OTC: EVFM) stockholders reject Aditxt merger; ends deal, pursues national listing Stock Titan

Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling PR Newswire

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem Stock Titan

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women PR Newswire

Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women PR Newswire

Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment Stock Titan

Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention PR Newswire

Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for Women PR Newswire

Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi® PR Newswire

Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders PR Newswire

Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal, On-Demand Prescription Contraceptive Vaginal Gel PR Newswire

Evofem Biosciences Announces Three New Phexxi™ Data Sets Accepted for Presentation at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting CNN